Holen Sie sich die Stockscreener-App
48.16
78.44%
21.17
Vorhandelsmarkt:
48.74
0.58
+1.20%
Schlusskurs vom Vortag:
$26.99
Offen:
$43.55
24-Stunden-Volumen:
19.68M
Relative Volume:
11.19
Marktkapitalisierung:
$3.04B
Einnahmen:
$18.09M
Nettoeinkommen (Verlust:
$-208.87M
KGV:
-13.71
EPS:
-3.5125
Netto-Cashflow:
$-178.15M
1W Leistung:
+79.57%
1M Leistung:
+78.04%
6M Leistung:
+109.12%
1J Leistung:
+225.63%
1-Tages-Spanne:
$42.50
$49.70
1-Wochen-Bereich:
$26.01
$49.70
52-Wochen-Spanne:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Firmenname
Uniqure Nv
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
48.16 | 1.76B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure Nv Aktie (QURE) Neueste Nachrichten
uniQure (QURE) investors approve share plan, charter and board at 2026 AGM - Stock Titan
[144] uniQure N.V. SEC Filing - Stock Titan
Don't Ignore The Insider Selling In uniQure - simplywall.st
This Insider Has Just Sold Shares In UniQure - Moomoo
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (QURE) director trades shares, receives RSUs and stock options - Stock Titan
Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer - Stock Titan
uniQure (QURE) director receives RSUs, stock options and sells shares for taxes - Stock Titan
uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes - Stock Titan
Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes - Stock Titan
Equity awards and tax-driven share sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (NASDAQ: QURE) director awarded RSUs, sells shares for taxes - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
symbol__ Stock Quote Price and Forecast - CNN
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
QURE Shareholder Alert: Investors With Losses May Seek to Lead t - GuruFocus
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
Fiera Capital Corp Invests $18.39 Million in uniQure N.V. $QURE - MarketBeat
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
What Just Happened with uniQure's Earnings and FDA Update - Kavout
QURE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesWeak Earnings Momentum - newsline.com
Director Kaye trades uniQure (QURE) shares in 10b5-1 option exercise and sale - Stock Titan
Huntingtons Disease Market Size to Hit USD 6.48 Billion by 2035 - Precedence Research
Mizuho downgrades UniQure NV (QURE) - MSN
Form 144 uniQure N.V. For: 3 June By Investing.com - Investing.com South Africa
uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE) - Seeking Alpha
Tracing UniQure's Tale Of Boom, Bust, And Rebound - RTTNews
(QURE) Volatility Zones as Tactical Triggers - Stock Traders Daily
uniQure stock surges 20% on Replimune FDA BLA news By Investing.com - Investing.com Australia
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
QURE News | UNIQURE NV (NASDAQ:QURE) - ChartMill
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
uniQure Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue, Stock SlipsCapex Guidance - newsline.com
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
uniQure N.V. (QURE) Stalls at $24.84 — Breakout or Breakdown? 2026-05-19PCR Moving Average - newsline.com
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
Finanzdaten der Uniqure Nv-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure Nv-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meek David D. | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
39,747 |
| Gut Robert | Director |
Jun 10 '26 |
Option Exercise |
16.04 |
2,645 |
42,426 |
34,987 |
| Gut Robert | Director |
Jun 10 '26 |
Sale |
26.05 |
7,552 |
196,720 |
27,435 |
| Gut Robert | Director |
Jun 11 '26 |
Sale |
27.06 |
2,726 |
73,766 |
32,259 |
| O'Keefe Kylie | Chief Customer & Strat Officer |
Jun 11 '26 |
Sale |
27.06 |
15,936 |
431,228 |
108,864 |
| Springhorn Jeremy P. | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,251 |
| POST LEONARD E | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
35,494 |
| Kaye Jack | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
25,996 |
| Jacques Rachelle Suzanne | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
33,903 |
| Balachandran Madhavan | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,254 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):